Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Open access

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for ∼15% of all leukemia. Progress of the disease from an indolent chronic phase to the more aggressive accelerated phase or blast phase (BP) occurs in a minority of cases and is associated with an accumulation of somatic mutations. We performed genetic profiling of 85 samples and transcriptome profiling of 12 samples from 59 CML patients. We identified recurrent somatic mutations in ABL1 (37%), ASXL1 (26%), RUNX1 (16%), and BCOR (16%) in the BP and observed that mutation signatures in the BP resembled those of acute myeloid leukemia (AML). We found that mutation load differed between the indolent and aggressive phases and that nonoptimal responders had more nonsilent mutations than did optimal responders at the time of diagnosis, as well as in follow-up. Using RNA sequencing, we identified other than BCR-ABL1 cancer-associated hybrid genes in 6 of the 7 BP samples. Uncovered expression alterations were in turn associated with mechanisms and pathways that could be targeted in CML management and by which somatic alterations may emerge in CML. Last, we showed the value of genetic data in CML management in a personalized medicine setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000943

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 2

  1. Mancini, 2017, SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia [abstract], Blood, 130, Abstract 43
  2. Baer, 2017, Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment [abstract], Blood, 130, Abstract 1585

Cited by

See all 73

Metadata

Authors
Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., Porkka, K., & Mustjoki, S.
Affiliations
  • Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;
  • University of Helsinki (FI)
  • Department of Pharmacology, Faculty of Medicine, and
  • Helsinki University Hospital (FI)
  • Cairo University (EG)
Corresponding author
Kankainen, Matti
Venue
Blood Advances
Published
2020-02-11
Volume
4
Issue
3
Pages
546-559
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3005797317
Cited by
67
References
69
Citations by year
2026: 5 · 2025: 11 · 2024: 12 · 2023: 10 · 2022: 11 · 2021: 13 · 2020: 5
FWCI
6.15
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
  • Finnish Cancer Institute
  • Incyte
  • Academy of Finland (287224, 292605 and 287224, 292605)
  • Suomen Kulttuurirahasto
  • Tekes (Dnro 6113/31/2016, 6113/31/2016)
  • Signe ja Ane Gyllenbergin Säätiö
  • China Scholarship Council
  • Syöpäjärjestöt
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
chronic myeloid leukemia, somatic mutations, mutation accumulation, blast crisis, c-Abl, ASXL1, RUNX1, BCOR, mutational signatures, acute myeloid leukemia, BCR-ABL1, gene expression profiling, mutational burden, treatment response, personalized medicine
MeSH terms
Mutation Accumulation, Blast Crisis, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000943
The paper
Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., Porkka, K., & Mustjoki, S. (2020). Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.